Artificial intelligence is compressing drug discovery timelines from years to months. The harder question is whether the pipeline being built serves patients or patents – an examination of the incentives, the hype, and who captures the value.
AI drug discovery is the pharmaceutical story of the decade, and the incentives behind it deserve the same scrutiny as the science. Evaluating any AI health claim starts with the same discipline – the free evaluation checklist is a good place to begin.